Vanguard Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-357,711
| Closed | -$1.4M | – | 4593 |
|
|
2023
Q3 | $1.4M | Buy |
357,711
+201,815
| +129% | +$1.38M | ﹤0.01% | 3718 |
|
|
2023
Q2 | $507K | Sell |
155,896
-2,523
| -2% | -$7.5K | ﹤0.01% | 4118 |
|
|
2023
Q1 | $573K | Hold |
158,419
| – | – | ﹤0.01% | 4090 |
|
|
2022
Q4 | $5.1M | Sell |
158,419
-2,702
| -2% | -$107K | ﹤0.01% | 3298 |
|
|
2022
Q3 | $6.74M | Buy |
161,121
+93,105
| +137% | +$4.26M | ﹤0.01% | 3155 |
|
|
2022
Q2 | $2.87M | Sell |
68,016
-9,210
| -12% | -$427K | ﹤0.01% | 3646 |
|
|
2022
Q1 | $5.24M | Buy |
77,226
+6,635
| +9% | +$552K | ﹤0.01% | 3505 |
|
|
2021
Q4 | $8.57M | Sell |
70,591
-4,203
| -6% | -$710K | ﹤0.01% | 3307 |
|
|
2021
Q3 | $10.5M | Buy |
74,794
+955
| +1% | +$189K | ﹤0.01% | 3213 |
|
|
2021
Q2 | $20.3M | Buy |
73,839
+6,178
| +9% | +$1.56M | ﹤0.01% | 2836 |
|
|
2021
Q1 | $14.5M | Buy |
67,661
+9,958
| +17% | +$2.75M | ﹤0.01% | 2954 |
|
|
2020
Q4 | $14M | Buy |
57,703
+13,355
| +30% | +$1.65M | ﹤0.01% | 2821 |
|
|
2020
Q3 | $4.67M | Buy |
44,348
+695
| +2% | +$63.3K | ﹤0.01% | 3182 |
|
|
2020
Q2 | $4.28M | Buy |
43,653
+22,317
| +105% | +$1.95M | ﹤0.01% | 3171 |
|
|
2020
Q1 | $1.6M | Buy |
21,336
+48
| +0.2% | +$4.57K | ﹤0.01% | 3358 |
|
|
2019
Q4 | $1.73M | Sell |
21,288
-108
| -0.5% | -$12.1K | ﹤0.01% | 3490 |
|
|
2019
Q3 | $2.61M | Sell |
21,396
-371
| -2% | -$51K | ﹤0.01% | 3363 |
|
|
2019
Q2 | $3.91M | Buy |
21,767
+184
| +0.9% | +$29.7K | ﹤0.01% | 3253 |
|
|
2019
Q1 | $3.45M | Buy |
21,583
+5,890
| +38% | +$1.17M | ﹤0.01% | 3278 |
|
|
2018
Q4 | $4.08M | Buy |
15,693
+3,703
| +31% | +$745K | ﹤0.01% | 3156 |
|
|
2018
Q3 | $2.92M | Buy |
11,990
+8,641
| +258% | +$2.26M | ﹤0.01% | 3408 |
|
|
2018
Q2 | $790K | Buy |
+3,349
| New | +$976K | ﹤0.01% | 3745 |
|
Other funds holding EVLO
Vanguard Group's EVLO Position: Q4 2023 in Review
Vanguard Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 357,711 shares — an estimated $1.4M sold.
Vanguard Group first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $20.3M in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Vanguard Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Vanguard Group sold 357,711 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $1.4M.
- Vanguard Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Vanguard Group's Evelo Biosciences, Inc. Common Stock position peaked at $20.3M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.